We recently reported that Amgen and Allergan had submitted an abbreviated Biologics License Application to the FDA for ABP 215, a biosimilar to Avastin® (bevacizumab). Today, the companies announced that they have also submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for this product.
Stay tuned to Big Molecule Watch for further developments.
The post Amgen and Allergan Submit European Application for Avastin® Biosimilar appeared first on Big Molecule Watch.